Kala Hopes To Stride Into Dry Eye Market This Year

 
• By Jo Shorthouse
  
Generate a summary of this article
Listen to this article
Beta

Kala Pharmaceuticals is hoping to shake up the dry eye market with a NDA filing this year for its steroid eye drop KPI-121 0.25%.

Vision
KPI-121 0.25% uses mucus-penetrating particle technology

Kala Pharmaceuticals Inc. is planning to file a new drug application in the US for what it hopes will become the first FDA-approved treatment for short-term dry eye disease, specifically dry eye flares. The $1.7bn dry eye market is currently dominated by Shire PLC and Allergan PLC, with Xiidra (lifitegrast) and Restasis (cyclosporine ophthalmic emulsion) respectively.

While the New Drug Application (NDA) for KPI-121 0.25% (loteprednol etabonate) will be based on existing clinical studies, STRIDE 1...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Sensory

Sponsored By

Nancy Tests SPARC-931 Part 8

This is a short description. This is a short description.

Small But Mitey: Tarsus To Amp Up Strong Xdemvy Launch

 
• By Alexandra Shimmings

Tarsus Pharmaceuticals is putting more sales and marketing heft behind its novel eyelid disease therapy, Xdemvy, to capitalize on a solid start in a previously untapped market.    

Acelyrin Belatedly Drops Izokibep In Its Lead Indications

 
• By Elizabeth Cairns

The group has stopped further development of the IL-17A inhibitor in hidradenitis suppurativa and psoriatic arthritis, and intends to pivot to a thyroid eye disease therapy.  

Aldeyra Readies Reproxalap For Dry Eye Refiling After Chamber Study Success

 
• By Mandy Jackson

The company said earlier this year that it would resubmit reproxalap for US FDA approval before the end of 2024 once it completed another Phase III trial and is eyeing both acute and chronic use.

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.